## CNC: Centene Corporation - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 9.5% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($42.04)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Centene Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20260105T163000 | Bullish | Relevance: 100%
- Centene Corp. (CNC) shares rose 6.94% to $44.68, outperforming the S&P 500 Index (SPX) and the Dow Jones Industrial Average (DJIA) on a favorable trading day for the stock market. This marked the stock's second consecutive day of gains.

**2. Barclays upgrades Centene stock rating to Overweight on ACA margin upside**
- Source: Investing.com | 20260105T112027 | Bullish | Relevance: 100%
- Barclays has upgraded Centene (NYSE:CNC) from Equalweight to Overweight and raised its price target to $54.00, citing potential margin improvements in the company's Affordable Care Act (ACA) exchange business. The upgrade is based on Centene's strong premium increases and stable competitive positioning expected to lead to 2.0% ACA margins by 2026, exceeding Street estimates for EPS in 2026 and 2027. Despite past challenges, Centene's financial health is rated "GREAT" by InvestingPro.

**3. Centene Corp. stock: Managed-care heavyweight tests investor patience as fundamentals outpace the share price**
- Source: AD HOC NEWS | 20260103T171833 | Neutral | Relevance: 100%
- Centene Corp. has shown quiet operational outperformance compared to peers, yet its stock has seen recent declines and remains below prior highs. Wall Street analysts are divided between cautious holds and selective buys, with future earnings and Medicaid contract decisions being critical to determining if Centene is a value trap or a contrarian investment. The company's focus on portfolio simplification and core government-backed healthcare programs, alongside careful management of medical costs, will be key to its future performance.

**4. Centene Corp. stock: Managed-care heavyweight tests investor patience as fundamentals outpace the share price**
- Source: AD HOC NEWS | 20260103T170741 | Neutral | Relevance: 100%
- Centene Corp. (CNC) stock has been in a standstill, experiencing a slight downward trend despite strong operational performance. The market appears to be weighing policy and Medicaid risks, but analysts remain cautiously optimistic, with price targets suggesting a 10-20% upside. The company's future hinges on Medicaid redeterminations, medical cost trends, and its internal efficiency programs.

**5. Barclays Upgrades Centene (CNC) with Raised Price Target | CNC S**
- Source: GuruFocus | 20260105T134304 | Bullish | Relevance: 100%
- Barclays has upgraded Centene (CNC) from "Equal-Weight" to "Overweight," raising its price target from $44.00 to $54.00, a 22.73% increase. Centene, a managed care organization focusing on government-sponsored healthcare plans, currently has an average brokerage recommendation of "Hold." GuruFocus estimates Centene's fair value (GF Value) at $100.66, suggesting a significant upside from its current price.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2026-01-05 | Barclays | $54 | $44 | +23% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2026-01-05 | Barclays | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($2.58M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 38.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.6% (-2.8%)
- Blackrock Inc.: 9.2% (+0.3%)
- State Street Corpora: 4.3% (-7.7%)
- AQR Capital Manageme: 3.0% (+76.6%)
- Geode Capital Manage: 2.6% (-4.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +7.6% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.69 elevated, pricing in significant growth expectations. Forward P/E 15.4x attractive for 43% earnings growth. Balance sheet: $1.1B free cash flow. Analyst sentiment positive (1 raises, avg +23%). Insider selling cluster ($2.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $22.0B |
| Beta | 0.48 |
| 52W Range | $25.08 - $66.81 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.69 |
| Forward P/E | 15.4 |
| Current P/E | 22.0 |
| YoY Growth | 42.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from 1.9% to 9.5% (+7.6% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (9.5% > 6.0%), caution on chasing. MRS_5 at 6.4% confirms short-term momentum alignment. Outperforming sector by 9.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI overbought at 76, risk of mean reversion. OFD pattern: +MTH (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 9.52% (CS: 96) | Strong |
| RSI_14 | 75.7 | Overbought |
| MACD Histogram | 0.31 | Bullish |
| vs SMA20 | 1.117x | Above |
| vs SMA50 | 1.179x | Above |
| vs SMA200 | 1.048x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $44.70
- **Stop Loss:** $42.04 (6.0% risk)
- **Target:** $47.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 324
- **Position Value:** $14,482.80
- **Portfolio %:** 14.48%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-03 (Est: $-1.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $0.50 | +404.3% |
| 2025Q2 | $0.21 | $-0.16 | -177.3% |
| 2025Q1 | $2.52 | $2.90 | +15.3% |
| 2024Q4 | $0.49 | $0.80 | +62.2% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*